Dealmaking activity in the US healthcare sector was robust in H1 2022 in the face of various macroeconomic headwinds. There were US$92.4 billion worth of deals announced in H1 2022. This was a 51 percent decrease from a...more
Despite the absence of megadeals, M&A in the sector climbed from 2020 levels thanks in part to strong PE and SPAC activity -
Healthcare and pharmaceutical deals continued at a robust pace through 2021, registering the...more
2/3/2022
/ Acquisitions ,
CFIUS ,
Domestic Dealmaking ,
Healthcare ,
Initial Public Offering (IPO) ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Private Equity ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs)
Heightened interest in medical suppliers, contract research organizations and biotech firms resulted in an impressive year for healthcare dealmaking-
Dealmaking within the pharma, medical and biotech sector continued from...more
12/21/2021
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Medical Research ,
Mergers ,
Special Purpose Acquisition Companies (SPACs) ,
Technology